Memantine augmentation for refractory obsessive–compulsive disorder

Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl- d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Progress in neuro-psychopharmacology & biological psychiatry Ročník 30; číslo 6; s. 1173 - 1175
Hlavní autori:	Pasquini, Massimo, Biondi, Massimo
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Amsterdam Elsevier Inc 30.08.2006 Elsevier
Predmet:	Adult Adult and adolescent clinical studies Anxiety disorders. Neuroses Biological and medical sciences Drug Resistance Drug Therapy, Combination Excitatory Amino Acid Antagonists - therapeutic use Female Glutamatergic transmission Humans Male Medical sciences Memantine Memantine - therapeutic use Memory for actions Middle Aged Neuropharmacology Obsessive-Compulsive Disorder - drug therapy Obsessive-Compulsive Disorder - psychology Obsessive-compulsive disorders Obsessive–compulsive disorder Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Serotonin Uptake Inhibitors - therapeutic use Obsessive–compulsive disorder Memantine Glutamatergic transmission Memory for actions Obsessive compulsive disorder Memory Anxiety disorder Glutamate receptor Antialzheimer agent Antiparkinson agent Amantadine dérivatives Obsessive-compulsive disorder Antagonist NMDA receptor
ISSN:	0278-5846, 1878-4216
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Glutamatergic hyperactivity hypothesis in obsessive–compulsive disorder (OCD) has been proposed but not tested. Memantine is an uncompetitive N-methyl- d-aspartate (NMDA) receptor antagonist. We report two cases of refractory obsessive–compulsive disorder treated with an augmentation of memantine at 15 mg/day. The first case did not benefit from such treatment, while the second showed immediate and substantial improvement. Contrasting results, reflecting different subtypes of OCD, are discussed. We hypothesized that in certain OCD subtypes an agent that enhances memory for actions may promote a reduction in orbitofrontal activation.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Case Study-2 ObjectType-Feature-4 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0278-5846 1878-4216
DOI:	10.1016/j.pnpbp.2006.04.013